Elanco Animal Health Inc - Company Profile
Powered by 
All the data and insights you need on Elanco Animal Health Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Elanco Animal Health Inc Strategy Report
- Understand Elanco Animal Health Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Elanco Animal Health Inc (Elanco) is a pharmaceutical company that develops and manufactures products for pet and farm animals. Its product portfolio includes parasiticides, vaccines, therapeutics, medicated feed additives, injectable antibiotics, insecticides, antibacterial, anticoccidials, and enzymes. The company also provides diagnostic tools, analytical services; animal health expertise; and separation anxiety and parasite control treatments. It offers the products and services to third-party distributors, dairy farmers, retail outlets, e-commerce channels, and aquaculture operators through various brands such as Rumensin, Trifexis, Credelio, Interceptor Plus, Maxiban, and Baytr. The company operates in the US, Brazil, Canada, China, France, Germany, Mexico, New Zealand, South Korea, Taiwan, and Vietnam. Elanco is headquartered in Greenfield, Indiana, the US.
Headquarters
United States of America
Address
2500 Innovation Way N, Greenfield, Indiana, 46140-9163
Website
www.elanco.com
No of Employees
9,300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ELAN (NYSE)
Revenue (2022)
$4.4B
0.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-1478.2%
(2022 vs 2021)
Market Cap*
$6.6B
Net Profit Margin (2022)
XYZ
-1,474.6%
(2022 vs 2021)
* As of and is in US$
Elanco Animal Health Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Parasiticides | Diagnostic Tools | Full Value Beef |
| Vaccines | Analytical Services | Dedicated |
| Therapeutics | Animal Health Expertise | Full Value Poultry |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company signed an agreement to divest its aqua business to Merck Animal Health, for US$1.3 billion. |
| 2023 | Contracts/Agreements | In November, the company announced a new global R&D collaboration with Novozymes to develop nutritional health products for beef cattle and dairy cows globally. |
| 2023 | Contracts/Agreements | In November, the company and Ducks Unlimited announced a partnership to emphasize the strong bond between environmental sustainability and agriculture specifically beef cattle production across North America. |
Competitor Comparison
| Key Parameters | Elanco Animal Health Inc | Zoetis Inc | Animal Science Products Inc | Boehringer Ingelheim Animal Health USA Inc | Danisco Animal Nutrition Division |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Greenfield | Parsippany | Nacogdoches | Ridgefield | - |
| State/Province | Indiana | New Jersey | Texas | Connecticut | - |
| No. of Employees | 9,300 | 14,100 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lawrence E. Kurzius | Chairman | Executive Board | 2024 | 65 |
| Jeffrey N. Simmons | President; Chief Executive Officer | Executive Board | 2018 | 55 |
| Todd S. Young | Executive Vice President; Chief Financial Officer | Senior Management | 2018 | 51 |
| James M. Meer | Chief Accounting Officer; Senior Vice President | Senior Management | 2018 | 53 |
| R. David Hoover | Director | Non Executive Board | 2024 | 77 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward